Cargando…

Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study

Detalles Bibliográficos
Autores principales:	Cortese, Andrea, Lozza, Alessandro, Vegezzi, Elisa, Alfonsi, Enrico, Moglia, Arrigo, Merlini, Giampaolo, Obici, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642003/ http://dx.doi.org/10.1186/1750-1172-10-S1-O13

Ejemplares similares

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

Diflunisal in late-onset FAP patients with moderate to severe neuropathy
por: Obici, Laura, et al.
Publicado: (2015)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
por: Cortese, Andrea, et al.
Publicado: (2015)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Analysis of disease progression in patients with transthyretin cardiac amyloidosis
por: Gilmore, Julian D, et al.
Publicado: (2015)

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2017)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

DISCOVERY: a study examining the prevalence of transthyretin mutations in subjects suspected of having cardiac amyloidosis
por: Akinboboye, Olakunle, et al.
Publicado: (2015)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
por: Gillmore, Julian D, et al.
Publicado: (2015)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis
por: Salvalaggio, Alessandro, et al.
Publicado: (2021)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers
por: Salvalaggio, Alessandro, et al.
Publicado: (2020)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021)

Liver‐directed drugs for transthyretin‐mediated amyloidosis
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
por: Obici, Laura, et al.
Publicado: (2016)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Delayed small bowel octreotide response in patients with hereditary transthyretin amyloidosis
por: Jonas, Wixner, et al.
Publicado: (2015)

P229 Three cases of easy to be misdiagnosed tinea of vellus hair
por: Liu, Wentao
Publicado: (2022)

Prion-like aspects of cerebral amyloidosis
por: Jucker, Mathias, et al.
Publicado: (2013)

Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)

Risk stratification in transthyretin-related cardiac amyloidosis
por: Scirpa, Riccardo, et al.
Publicado: (2023)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u4gfrgab683g4022vjteofqn5n